Acid Suppression and Chemoprevention in Barrett’s Oesophagus
- 1 September 2004
- journal article
- review article
- Published by S. Karger AG in Digestive Diseases
- Vol. 22 (2) , 171-180
Abstract
Barrett’s oesophagus is a pre-malignant condition affecting 1% of the population in the West. Even though most patients with Barrett’s will not develop oesophageal cancer, the incidence of adenocarcinoma is 0.45–1%, conferring a 40-fold increased risk compared with the general population. The risk rises to 40–50% within 5 years for those with high grade dysplasia. Currently, the only strategies available to diminish adenocarcinoma rates are surveillance endoscopy, endoscopic thermal or photodynamic ablation or tissue resection. The latter options are reserved for those who already have dysplasia. 10–50% of patients undergoing oesophagectomy for high grade dysplasia have been shown to have adenocarcinoma. Therefore approaches are needed to be that either remove or prevent stimuli propelling patients down the dysplasia-adenocarcinoma pathway. Both gastric acid and bile acids have been reported as potential insults involved in the pathogenesis of Barrett’s oesophagus. This is thought to be mediated by a range of molecules including cyclo-oxygenase-2, c-myc and mitogen-activated protein kinase signalling. Proton pump inhibitors not only suppress acid but also bile reflux, although symptom control is a poor guide as to adequacy of acid suppression. There is some evidence that proton pump inhibitors cause partial regression in Barrett’s oesophagus length, although the data is contradictory. Proton pump inhibitors have also been shown to increase cell differentiation and apoptosis, reduce proliferation and COX-2 levels, with the supposition that this may diminish cancer risk. However this role in decreasing cancer risk has not yet been evaluated. The use of NSAIDS and aspirin, most likely via inhibition of COX-2 and other inflammatory pathways, is associated with a reduction of adenocarcinoma rates. Both PPIs and NSAIDs/Aspirin may therefore be potential chemopreventative agents but further studies are required to appraise their use.Keywords
This publication has 39 references indexed in Scilit:
- Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathwaysOncogene, 2003
- Mortality study of 18 000 patients treated with omeprazoleGut, 2003
- Observer variation in the diagnosis of superficial oesophageal adenocarcinoma: another spanner in the works?Gut, 2002
- Tumour necrosis factor-α in Barrett's oesophagus: a potential novel mechanism of actionOncogene, 2002
- Barrett's esophagusJournal of Gastroenterology, 2002
- Helicobacter pyloriInfection and the Development of Gastric CancerNew England Journal of Medicine, 2001
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Proton pump inhibitors for Barrett's oesophagusGut, 2000
- Regression of columnar‐lined (Barrett’s) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapyAlimentary Pharmacology & Therapeutics, 1999
- Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2Cell, 1995